| 產(chǎn)品編號 | bsm-60011M |
| 英文名稱 | Mouse Anti-3-Nitrotyrosine antibody |
| 中文名稱 | 硝基酪氨酸/硝基化酪氨酸單克隆抗體 |
| 別 名 | NO tyrosine; nTyr; Nitrotyrosine; nitro-Tyrosine; nitro Tyrosine. 酪氨酸硝基化； |
| 產(chǎn)品類型 | 小分子抗體 特殊修飾抗體 |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號轉(zhuǎn)導(dǎo) Alzheimer's |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human (predicted: Mouse,Rat,Nitrotyrosine,All) |
| 產(chǎn)品應(yīng)用 | WB=1:500-1000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 細(xì)胞定位 | 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Nitrotyrosine |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Nitrotyrosine is a marker for inflammation and nitric oxide (NO) production and is formed in the presence of the active metabolite NO. Because nitrotyrosine is a stable product of multiple pathways, such as the formation of peroxynitrite, its plasma concentration may be a useful determinant of NO-dependent damage in vivo. Nitrotyrosine has been detected in inflammatory processes such as septic shock, rheumatoid arthritis, celiac disease, atherosclerotic plaques and chronic renal failure. Protein tyrosine nitration results in a post-translational modification that is increasingly receiving attention as an important component of nitric oxide signaling. While multiple nonenzymatic mechanisms are known to be capable of producing nitrated tyrosine residues, most tyrosine nitration events involve catalysis by metalloproteins such as myeloperoxidase, eosinophilperoxidase, myoglobin, the cytochrome P-450s, superoxide dismutase and prostacyclin synthase. Various studies have shown that protein tyrosinenitration is limited to specific proteins and that the process is selective. For example, exposure of human surfactant protein A, SP-A, to oxygen-nitrogen intermediates generated by activated alveolar macrophages resulted in specific nitration of SP-A at tyrosines 164 and 166, while addition of 1.2 mMCO 2 resulted in additional nitration at tyrosine 161. The presence of nitrotyrosine-containing proteins has shown high correlation to disease states such as atherosclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. SWISS: N/A CAS: 621-44-3 |
| 產(chǎn)品圖片 |
Blocking buffer: 5% NFDM/TBST
Primary ab dilution: 1:1000
Primary ab incubation condition: bsm-60011M, 2
hours at room temperature
Secondary ab: Goat Anti-Mouse IgG H&L
(HRP)
Lysate: HeLa±peroxynitrite (3mM, 30 mins)，
MEF±peroxynitrite (3mM, 30 mins)，
HeLa±pervanadate(3mM, 30 mins)
Protein loading quantity: 20 μg
Exposure time: 60 s
Predicted MW: Multiple kDa
Observed MW: Multiple kDa
Blocking buffer: 5% NFDM/TBST
Primary ab dilution: 1:1000
Primary ab incubation condition: bsm-60011M, 2
hours at room temperature
Secondary ab: Goat Anti-Mouse IgG H&L
(HRP)
Lysate: HeLa±peroxynitrite (3mM, 30 mins)，
MEF±peroxynitrite (3mM, 30 mins)，
HeLa±pervanadate(3mM, 30 mins)
Protein loading quantity: 20 μg
Exposure time: 60 s
Predicted MW: Multiple kDa
Observed MW: Multiple kDa
|
